A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Outpatients With Bipolar Disorder and Alcohol Use Disorders
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Alcohol dependence is extremely common in patients with bipolar disorder, and it is associated with unfavorable outcomes, including treatment nonadherence, violence, and cognitive impairment. However, few treatment trials have been conducted in this population. Quetiapine is an atypical antipsychotic medication that is used to treat the mood symptoms of bipolar disorder. In this study, the efficacy of quetiapine in reducing alcohol use and improving mood symptoms was assessed in patients with bipolar disorder and alcohol abuse or dependence. METHOD: One hundred fifteen outpatients with bipolar disorder and alcohol abuse or dependence were randomly assigned to 12 weeks of quetiapine (titrated to 600 mg/day) add-on therapy or placebo. Alcohol use and mood were assessed. The study was conducted from November 2002 to September 2005. RESULTS: One hundred two participants (49% with bipolar I disorder, 82% depressed, and 97% with alcohol dependence) returned for at least 1 postbaseline assessment and were used in the random regression analysis. No statistically significant between-group differences were found on alcohol use measures or the Young Mania Rating Scale. However, based on a random regression analysis, scores on the Hamilton Rating Scale for Depression (HAM-D) decreased statistically significantly more in the quetiapine than in the placebo group during the trial (p < .05). The between-group difference was largely due to differences in HAM-D scores during the first 6 weeks of the trial, with the placebo group showing greater improvement during the second half of the trial. CONCLUSIONS: Quetiapine therapy was associated with a statistically significant decrease in depressive symptoms, but not alcohol use, in patients with bipolar disorder and alcohol dependence (p < .05).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“, 2008), but the limited literature is mixed (Brown et al., 2008), preventing empirical guidance.”
BackgroundLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“An RCT of add-on quetiapine (600 mg/day) found no improvement in alcohol use or craving in those with bipolar disorder and alcohol abuse or dependence (Brown et al., 2008) (Ib).”
BackgroundCurrent Status of Co-Occurring Mood and Substance Use Disorders: A New Therapeutic Target
Pettinati, H. M., O’Brien, C. P., & Dundon, W. D. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010112 · Cited by 252
“Results of the trials revealed that no additional benefit was achieved in reducing either depressive or manic symptoms (29, 31–34), with one exception: patients with bipolar disorder taking quetiapine in addition to treatment as usual showed a reduction in depressive symptoms compared with placebo treatment (30), alth…”
BackgroundTreatment of Dual Diagnosis Disorders
Murthy, P., & Chand, P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328351a3e0 · Cited by 115
Swann, A. C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05146.x · Cited by 109
Stedman, M., Pettinati, H. M., Brown, E. S., Kotz, M., Calabrese, J. R., & Raines, S. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01270.x · Cited by 70
Self-citationGoldstein, B. I., Strober, M., Axelson, D., Goldstein, T. R., Gill, M. K., Hower, H., Dickstein, D., Hunt, J., Yen, S., Kim, E., et al. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.07.009 · Cited by 65
Thekiso, T. B., Murphy, P., Milnes, J., Lambe, K., Curtin, A., & Farren, C. K. (2015) · Behavior Therapy · doi:10.1016/j.beth.2015.05.005 · Cited by 60
Brown, E. S., Davila, D., Nakamura, A., Carmody, T. J., Rush, A. J., Lo, A., Holmes, T., Adinoff, B., Caetano, R., Swann, A. C., et al. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12445 · Cited by 50
“The observation that quetiapine was not superior to placebo in reducing craving is consistent with prior quetiapine studies in alcohol dependence (Brown et al., 2008; Guardia et al., 2011; Litten et al., 2012; Stedman et al., 2010), with the exception of the study by Kampman and colleagues (2007)…”
BackgroundMethodResultInfluentialSelf-citationBeaulieu, S., Saury, S., Sareen, J., Tremblay, J., Schütz, C. G., McIntyre, R. S., & Schaffer, A. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400105 · Cited by 38
“75,76 One 20-week, double-blind, head-to-head RCT comparing quetiapine (mean dose: 301.9 mg/d; n = 42) and risperidone (mean dose: 3.1 mg/d; n = 38) for cocaine or methamphetamine use in BD found positive improvements in drug craving ( P < .0005) and in overall drug use ( P = .03) in both treatment…”
InfluentialOff-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
Metadata
- Authors
- Brown, E. S., Garza, M., & Carmody, T. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-05-15
- Volume
- 69
- Issue
- 5
- Pages
- 701-705
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2054298033
- Cited by
- 101
- References
- 0
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.